BioSpace News Archive

Regeneron Pharmaceuticals, Inc. and Sanofi announced results from a Phase 3 open-label extension trial demonstrating the efficacy and safety profile of Dupixent® as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation.

Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Dizal reported the promising safety and pharmacokinetic data from the global Phase I study of DZD1516 in patients with HER2 positive metastatic breast cancer who relapsed from multiple prior treatments at the 2022 European Society for Medical Oncology Annual Meeting.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 as a universal COVID-19 booster vaccine candidate.

Bertis announced on the 5th that the research results of their search for protein biomarkers for early diagnosis of high-grade serous ovarian cancer were published in the September issue of the international scientific journal, Journal of Proteome Research.1 This press release features multimedia.

Tyra Biosciences, Inc. announced that the Company will be presenting preclinical data on TYRA-300 during a poster session at the European Society for Medical Oncology 2022 Congress, being held in person September 9-13, 2022 in Paris, France.